A placebo-controlled trial found that psilocybin, the active ingredient in magic mushrooms, led to significant and lasting reductions in symptoms of obsessive-compulsive disorder (OCD). The study involved 28 adults who had struggled with OCD for an average of two decades and had not found relief with previous treatments. Participants were given a single dose of psilocybin or a placebo and the results suggest psilocybin could offer a novel treatment approach.
– the active ingredient in magic mushrooms – produces rapid reductions in symptoms of obsessive-compulsive disorder , according to the first placebo-controlled trial to test the psychedelic for the mental health condition.
The effects also seem to persist for at least 12 weeks, suggesting that psilocybin could provide lasting relief.at Imperial College London, who wasn’t involved in the research. “The whole point of OCD therapy is about teaching people to behave differently. So, rather than check the lights 15 times, you check them twice.”, a condition characterised by obsessive thoughts and compulsive habits, which can be overwhelming. Treatments tend to include talking therapies and antidepressants, butat Yale School of Medicine and his colleagues decided to test psilocybin for OCD in the first randomised, placebo-controlled trial. The team recruited 28 adults who had lived with OCD for two decades, on average, and had unsuccessfully tried at least two different treatments. They all had the severity of their symptoms rated using a standard scale, which gives a score of between 0 and 40. They were then randomly assigned to either receive a single oral dose of psilocybin or niacin , also known as vitamin B3, which acted as the placebo.Your science-backed guide to the easy habits that will help you sleep well, stress less, eat smarter and age better.The psilocybin dose was enough to give the participants a psychedelic trip, which tends to involve big changes in perception, thoughts and emotion. “It’s pretty intense, though it varies from person to person,” says Pittenger. After 48 hours, the symptom scores of the 14 people who received psilocybin decreased by 9.76 points, on average, while those taking niacin stayed about the same. “The speed and durability of the improvement seen after a single dose of psilocybin are remarkable,” saysOne week later, about 70 per cent of those who took psilocybin still had a symptom score reduction of about 35 per cent, and the benefits persisted at a 12-week follow-up. “It’s definitely better and faster than other medications for OCD,” says Nutt, who was involved in a recent trial, without a placebo group, that similarly found Kwan says that seeing such an improvement in people who have already tried multiple standard treatments suggests that psilocybin engages the brain in a fundamentally different way, but it’s exact mechanism for helping with OCD is unclear. “If we can uncover that biology, it could transform how we think about treating many psychiatric disorders, not only OCD,” he says. One idea is that psilocybin enhances the plasticity of the brain, so thoughts that seemed rigid and dominant can become less powerful. That is profound with all psychedelics, says Nutt, who recently showed that one dose of the psychedelic. “Previously, depressive thoughts dominated their thinking, but after the psychedelic, their brain is more flexible and they put them to one side instead of agreeing with them,” he says.In children with anorexia nervosa or other restrictive eating disorders, changes in the brain’s outer layer don’t seem to be due to lack of nutrition alone – and some mirror those seen in other neurological conditions Another idea is that psilocybin recalibrates the relationship between the brain’s default mode network, which is involved in rumination and the sense of self, and its other areas, says Pittenger. We also know that a single dose of But the drug could have safety concerns. During the Yale study, one person who already had persistent thoughts about suicide began to actively plan it. The danger passed after standard monitoring, but Pittenger says this highlights the need for clinical safeguards to be in place when administering psilocybin medically. Larger trials also need to confirm the drug’s efficacy and safety, the best dose and who is most likely to benefit or be at risk, he says. Another recurring problem with psychedelic research is that the effects of these drugs mean that trial participants can often gauge whether they have received them or a placebo. The team tried to mitigate this by using a dose of niacin that can cause psychedelic-like events, such as flushing and an elevated heart rate. Nevertheless, Pittenger says that most of the participants still had a clear idea of what they had received. “This is a weakness of the study, as it is for most such work in the field,” he says.
Psilocybin OCD Mental Health Clinical Trial Treatment
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AI's promise and peril examined in 2 new documentariesArtificial intelligence’s dystopian specter has spawned a pair of documentaries dissecting a technology that’s depicted as ravenous parasite devouring humanity’s knowledge, creativity and empathy.
Read more »
Sui’s native USDsui stablecoin goes live with promise of Treasury yield going back to ecosystemPlans for a Sui Dollar, which is issued by stablecoin firm Bridge, were introduced toward the end of last year.
Read more »
Foxborough still won't license World Cup yet, even after funding promiseThe fate of the Foxborough entertainment license that will allow FIFA men’s world cup games to be played at Gillette stadium this summer is still up in the air. Funding questions for security seem to be resolved, but the town’s select board still has other quarrels with the organizers.
Read more »
Key Stat From Braves Michael Harris II Reveals Promise for 2026 SeasonThe Atlanta Braves center fielder is slowly establishing the foundation for what could be a big season ahead
Read more »
Magic City Claps Back Over Hawks Tribute Night Backlash, Promise No NudityLuke Kornet might wanna peep this -- the folks at Magic City are addressing the backlash surrounding their tribute at an upcoming Atlanta Hawks game ... saying the establishment has so much more to offer than just strippers.
Read more »
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsyEva Amsen is a science writer in London. Her articles about biology, chemistry, environmental sciences and the overlap of science and the arts have appeared in Undark, The Observer (Guardian), Nature, Hakai, Nautilus, Forbes.com and other publications.
Read more »